Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals Q3 2025 Earnings Report

Enanta Pharmaceuticals logo
$15.16 +7.26 (+91.90%)
Closing price 04:00 PM Eastern
Extended Trading
$15.01 -0.15 (-0.96%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals EPS Results

Actual EPS
-$0.85
Consensus EPS
-$1.25
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Enanta Pharmaceuticals Revenue Results

Actual Revenue
$18.31 million
Expected Revenue
$16.21 million
Beat/Miss
Beat by +$2.10 million
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Enanta Pharmaceuticals' Q4 2025 earnings is scheduled for Monday, November 24, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enanta Pharmaceuticals Earnings Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections. Its lead RSV program, EDP-938, is an orally administered inhibitor designed to block viral replication and is being evaluated in Phase 2 clinical trials for both adult and pediatric populations. In addition to RSV, Enanta is advancing preclinical candidates against hepatitis B virus (HBV) and other respiratory pathogens, seeking to apply its structure-based drug design approach to a broader array of infectious diseases.

Founded in 1997 by a team of chemists and virologists, Enanta has established collaborative relationships with large pharmaceutical firms to accelerate the development and commercialization of its antiviral compounds. These partnerships have provided non-dilutive funding and clinical development support, while allowing Enanta to retain rights to key programs in certain territories.

Under the leadership of President and Chief Executive Officer Jay R. Luly, the company continues to expand its scientific capabilities and manufacturing collaborations. Enanta maintains research facilities in Massachusetts and works with contract development and manufacturing organizations to advance its pipeline. With a focus on unmet medical needs in viral diseases, Enanta aims to bring novel oral therapies to patients worldwide.

View Enanta Pharmaceuticals Profile

More Earnings Resources from MarketBeat